IBI3001是由信达生物基于其B7-H3/EGFR双抗IBI334研发的一款 B7-H3/EGFR 双抗 ADC 药物,采用了定点偶联的方法,该研究入选2024 AACR 突破性研究(Late-Breaking Research)(图1)[1]。 图1. IBI3001的AACR摘要 此前,信达在 IBI334 研究中证明: 1. B7-H3 和 EGFR 在多个实体瘤中共表达; 2.B7-H3辅助的EGFR...
2023. Individuals interested in joining the AACR and sponsoring a clinical trial or late-breaking abstract must submit an application for membership no later than January 3, 2024. Membership questions may be directed
2023. Individuals interested in joining the AACR and sponsoring a clinical trial or late-breaking abstract must submit an application for membership no later than January 3, 2024. Membership questions may be directed
for the treatment of advanced prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial
Lung05 (DL-05) trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl): Abstract nr CT248...
Lung05 (DL-05) trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Ph...
Late-breaking presentation Candidate: Autogene cevumeran (BNT122, RO7198457) Session Title: “Cancer Vaccines: Ready for Prime Time?” Abstract Title: “Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer” ...
Abstract:AK131, an anti-PD1/CD73 bispecific antibody for cancer immune therapy https://www.abstractsonline.com/pp8/#!/10517/presentation/17745 AK131 is a bi-specific antibody derived from Penpulimab (Akeso's marketed PD-1 antibody ) and AK119 (Akeso's CD73 antibody in clinical stage). ...
IBI3001是由信达生物基于其B7-H3/EGFR双抗IBI334研发的一款 B7-H3/EGFR 双抗 ADC 药物,采用了定点偶联的方法,该研究入选2024 AACR 突破性研究(Late-Breaking Research)(图1)[1]。 图1. IBI3001的AACR摘要 此前,信达在 IBI334 研究中证明: 1. B7-H3 和 EGFR 在多个实体瘤中共表达; ...
Regular Abstract Withdrawal Deadline:February 9, 2024 - 常规摘要撤回截止日期 Late-Breaking and Clinical Trials Abstract Notifications Sent:February 12, 2024 - 发送LBA和临床试验摘要接收结果 Late-Breaking and Clinical Trials Abstract Withdrawal Deadline:February 23, 2024 ...